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INTRODUCTION 
Quitlines help smokers to stop but few studies have explored how behavioural 
and medicinal interventions can be optimally delivered via this route [1]. One of 
these was the PORTSSS trial, which found that offering free Nicotine Replacement 
Therapy (NRT) vouchers did not increase cessation rates when compared to no 
offer [2]. It also found that a ‘proactive’, more intensive, call regime from/to 
clients did not improve cessation rates over ‘usual care’.  Was it possible that 
participants who did not receive a voucher for NRT, sought out and used other 
forms of cessation support, which minimised any effect of receiving the NRT 
voucher? Use of ‘non-trial’ support varied across PORTSSS trial intervention 
groups and, in this analysis, we sought to determine whether or not use of this 
substantially affected trial findings. 
METHODS 
Our secondary analysis included all 2591 randomised participants of the PORTSSS 
trial. PORTSSS was a RCT of an English, government-funded quitline, comparing 
two forms of behavioural support, with and without the offer of a free NRT 
voucher using a parallel group, factorial 2x2 design. Non-trial support used by 
participants included (n; %): ‘over the counter’ NRT (498; 19.2%), NRT from 
health professionals (479; 18.5%), bupropion (37; 1.4%), varenicline (165; 
6.4%), NHS stop smoking service support (125; 4.8%), NHS one-to-one therapy 
(221; 8.5%) and non-NHS quitline (40; 1.5%); any support (978; 37.7%). 
Binary variables were created for each support type with recipients coded as 1 
and non-recipients, 0.  We used the same multivariable regression model as in 
the original trial analysis with the effect of treatment group adjusted for age, 
gender, age of finishing education, and heaviness of smoking, and then 
additionally adjusted for each of the binary indicators of use of non-trial support 
to assess whether this altered the effect of treatment.   
RESULTS 
3 
 
Comparison of the two adjusted models (Table 1) shows little difference to the 
trial findings with respect to the primary outcome, prolonged cessation at 6 
months (trial model OR 0.86, 95% CI 0.7-1.06; additional model OR 0.84, 95%CI 
0.66-1.07) or any of the secondary outcomes, irrespective of whether self-
reported or validated smoking outcomes are used.  
 
DISCUSSION 
To our knowledge, this is the first analysis to investigate the effect of additional 
cessation support on the impact of free NRT provision from a quitline.  The 
findings suggest that use of such support does not explain the negative PORTSSS 
trial findings with respect to NRT.  We have identified only one other paper 
investigating associations between quitline outcomes and use of other forms of 
support [3]; it found that smokers who had used other types of cessation support 
prior to quitline enrolment, were more likely to subsequently stop smoking with 
quitline help.  Little is known about the relative contributions of quitline and non-
quitline support to smoking cessation; monitoring and evaluating the relationship 
of ‘non-trial’ cessation support to outcomes in future quitline studies is important. 
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Table 1: Smoking cessation outcomes in relation to Nicotine Replacement Therapy 
 Total  
 
N=2591 
No NRT  
 
N = 1296 
NRT  
 
N = 1295 
Unadjusted OR  
(95% CI; p value) 
 
Adjusted OR* (95% CI; p 
value) 
Adjusted OR** (95% CI; p 
value) 
Outcomes at 6 months  n (%) 
Prolonged cessation (inc. 
questionnaire data) (Primary 
outcome)  
490 (18.9%) 261 (20.1%) 229 (17.7%) .85 (.70, 1.04; p = 0.11) 0.86 (0.70, 1.06; P = 0.16) 
 
0.84 (0.66-1.07; p = 0.17) 
CO Validated prolonged 
cessation  
207 (8.0%) 122 (9.4%) 85 (6.6%) .67 (.50, 0.90; p = 0.008) 0.65 (0.48, 0.88; P = 
0.005) 
 
0.63 (0.45-0.86; p = 0.004) 
 
Self-reported cessation for 
>= 7 days 
531 (20.5%) 283 (21.8%) 248 (19.1%) .85 (.70, 1.03; p = 0.09) 0.85 (.70, 1.04; p = 0.13) 
 
0.85 (0.67-1.07; p = 0.17) 
CO Validated cessation for >= 
7 days  
200 (7.7%) 119 (9.2%) 81 (6.2%) .66 (.49, .88; p = 0.006) 0.64 (0.47, 0.87; P = 
0.004) 
 
0.62 (0.45-0.86; p = 0.004) 
Reported cessation for >= 3 
months  
 
401 (15.5%) 216 (16.6%) 185 (14.3%) .83 (.67, 1.03; p = 0.09) 0.84 (0.67, 1.05; P = 0.14) 
 
0.86 (0.66-1.10; p=0.23) 
Reports one or more quit 
attempts lasting > 24 hrs** 
594 (22.9%) 289 (22.3%) 305 (23.5%) 1.07 (0.88-1.28; p=0.49) 1.05 (0.86-1.27; p=0.60) 
 
1.15 (0.88-1.50; p = 0.30) 
Median (IQR) no. quit 
attempts reported 
2 (1-3) 2 (1-4) 2 (1-3) n/a n/a n/a 
Outcomes at 1 month  
Prolonged cessation since quit 
date  
1040 
(40.1%) 
520 (40.1%) 520 (40.1%) 0.99 (.85, 1.16; p = 0.93) 1.01 (0.86, 1.19; P = 0.88) 
 
1.00 (0.80-1.26; p = 0.96) 
Reported cessation for >= 7 
days  
831 (32.0%) 417 (32.2%) 414 (32.0%) .98 (.83, 1.16; p = 0.85) 0.99 (0.84, 1.18; P = 0.97) 
 
0.97 (0.77-1.22; p=0.80) 
*Adjusted for age, gender, educational level and heaviness of smoking index;  2397 cases included in adjusted analyses.  
** Additionally adjusted for all forms of non-trial support.
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